Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
- 31 March 1999
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 35 (3) , 410-412
- https://doi.org/10.1016/s0959-8049(98)00403-1
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsPublished by Elsevier ,1997
- The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of viewCritical Reviews in Oncology/Hematology, 1995
- Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomideBritish Journal of Cancer, 1994
- Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cellsBritish Journal of Cancer, 1993
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 1992
- High-dose DTIC in advanced soft-tissue sarcomas in the adultAnnals of Oncology, 1991